Focus Surgery Seeks IDE For Sonablate HIFU Prostate Cancer Treatment
This article was originally published in The Gray Sheet
Executive Summary
Focus Surgery says it will file an investigational device exemption application with FDA in mid-to-late 1999 to begin U.S. clinical trials of the Sonablate 200 high-intensity focused ultrasound (HIFU) system for treatment of prostate cancer.
You may also be interested in...
Misonix Sonablate PMA Submission For BPH Expected In September
Misonix is looking toward a late September premarket approval application filing date for the Sonablate 200 high intensity focused ultrasound (HIFU) device in treating benign prostatic hyperplasia. Commercial release of the product in the U.S. is expected sometime in 2001.
Philips Portfolio Includes ‘No Single Product That Does Not Use A Type Of AI,’ Says CEO And AI Thought Leader Roy Jakobs
Philips CEO Roy Jakobs talks to Medtech Insight about the medtech firm’s decade-long history of embedding AI into its products and what he expects from the newly released draft framework by the National Academy of Medicine, which he helped develop as co-chair of the Steering Committee.